Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist

Brain Research

Volumn 838, Issue 1-2, 1999, Pages 51-59

  Iida, Motoyuki ^a   Miyazaki, Ikuko ^a   Tanaka, Ken Ichi ^a   Kabuto, Hideaki ^a   Iwata Ichikawa, Emi ^a   Ogawa, Norio ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Antioxidant; Catalase; Free radical; Glutathione (GSH); Neuroprotection; PD; Superoxide dismutase (SOD)

Indexed keywords

CATALASE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; FREE RADICAL; GLUTATHIONE; OXIDOPAMINE; ROPINIROLE; SCAVENGER; SULPIRIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID PEROXIDATION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; CORPUS STRIATUM; DOPAMINE AGONISTS; FREE RADICAL SCAVENGERS; INDOLES; MALE; MICE; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; SUPEROXIDES;

EID: 0033554203     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01688-1     Document Type: Article

References (45)

1. Adams J.D. Jr., Odunze I.N. Oxygen free radicals and PD. Free Radic. Biol. Med. 10:1991;161-169.
2. Aebi H. Catalase in vitro. Methods Enzymol. 105:1984;121-126.
3. Ambani L.M., Van Woert M.H., Murphy S. Brain peroxidase and catalase in PD. Arch. Neurol. 32:1975;114-118.
4. Asanuma M., Ogawa N., Nishibayashi S., Kawai M., Kondo Y., Iwata E. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Arch. Int. Pharmacodyn. Ther. 329:1995;221-230.
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72:1976;248-254.
6. J.A. Buege, S.D. Aust, Microsomal lipid peroxidation, in: S. Fleisher, L. Packer (Eds.), Methods in Enzymology, Academic Press, New York, 1978, pp. 302-310.
7. Cedarbaum J.M., Gandy S.E., McDowell F.H. "Early" initiation of levodopa treatment does not promote the development of motor fluctuations, dyskinesias, or dementia in PD. Neurology. 41:1991;622-629.
8. Chase T.N., Mpuradian M.M., Engber T.M. Motor response complications and the function of striatal efferent systems. Neurology. 43:1993;S23-S26. Suppl. 6.
9. G. Cohen, Oxidative stress in the nervous system, in: H. Sies (Eds.), Oxidative Stress, Academic Press, New York, 1985, pp. 383-402.
10. Cohen G. Monoamine oxidase, hydrogen peroxide, and PD. Adv. Neurol. 45:1986;119-125.
11. Dexter D.T., Wells F.R., Lees A.J., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in PD. J. Neurochem. 52:1989;1830-1836.
12. Fahn S. Controversies in the therapy of PD. Adv. Neurol. 69:1996;477-484.
13. Feltem D.L., Felten S.Y., Fuller R.W., Romano T.D., Smalstig E.B., Wong D.T., Clemens J.A. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol. Aging. 13:1992;339-351.
14. Friedman A., Siienkiewicz F. Psychotic complications of long-term levodopa treatment of PD. Acta Neuropathol. Scand. 84:1991;111-113.
15. Gassen M., Glinka Y., Pinchasi B., Youdim M.B.H. Apomorphine is a potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308:1996;219-225.
16. C.G. Goetz, Dopaminergic agonists in the treatment of PD, in: C.W. Olanow, A.N. Lieberman (Eds.), The Scientific Basis for the Treatment of PD, Parthenon Publishing Group, Carnforth, 1992, pp. 157-174.
17. Gómez-Vargas M., Nishibayashi-Asanuma S., Asanuma M., Kondo Y., Iwata E., Ogawa N. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res. 790:1998;202-208.
18. Hoehn M.M.M. PD: progression and mortality. Adv. Neurol. 45:1986;457-461.
19. Jankovic J., Orman J. Parallel double-blind study of pergolide in PD. Adv. Neurol. 45:1986;551-553.
20. Jenner P. The rationale for the use of dopamine agonists in PD. Neurology. 45:1995;S6-S12. Suppl. 3.
21. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of PD. Neurology. 47:1996;161-170.
22. Jenner P., Schapira A.H.V., Marsden C.D. New insights into the cause of PD. Neurology. 42:1992;2241-2250.
23. Kish S.J., Morito C., Hornykiewicz O. Glutathione peroxidase activity in PD. Neurosci. Lett. 58:1985;343-346.
24. Kondo T., Ito T., Sugita Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Neurobiology. 738:1994;222-229.
25. Lange K.W., Rausch W.-D., Gsell W., Naumann M., Oestreicher E., Riederer P. Neuroprotection by dopamine agonists. J. Neural Transm. 43:1994;183-201. Suppl.
26. Lieberman A.N., Goldstein M., Leibowitz M., Gopinathan G., Neophytides A., Hiesiger E., Nelson J., Walker R. Long-term effects of pergolide. Neurology. 33:1983;112. Suppl. 2.
27. Marsden C.D., Parkes J.D. "On-off" effects in patients with PD on chronic levodopa therapy. Lancet. i:1976;292-296.
28. Nishibayashi S., Asanuma M., Kohno M., Gómez-Vargas M., Ogawa N. Scavenging effects of dopamine agonists on nitric oxide radicals. J. Neurochem. 67:1996;2208-2211.
29. Nutt J.G., Woodward W.R., Hammerstad J.P., Carter J.H. The "on-off" phenomenon in PD. N. Engl. J. Med. 310:1984;483-488.
30. Oberley L.W., Spitz D.R. Assays of superoxide dismutase activity in tumor tissue. Methods Enzymol. 105:1984;457-464.
31. N. Ogawa, Neuroprotection with dopamine agonists, in: C.W. Olanow, J.A. Obeso (Eds.), Beyond the Decade of the Brain: Dopamine agonists in early PD, Wells Medical, Kent, 1997, pp. 195-200.
32. Ogawa N., Edamatsu R., Mizukawa K., Asanuma M., Kohno M., Mori A. Degeneration of dopaminergic neurons and free radicals: possible participation of levodopa. Adv. Neurol. 60:1993;242-250.
33. Ogawa N., Haba K., Asanuma M., Mori A. Long-lasting effect of ceruletide on dyskinesia and monoaminergic neuronal pathways in rats treated with iminodipropionitrile. Brain Res. 556:1991;271-279.
34. Ogawa N., Tanaka K., Asanuma M., Kawai M., Masumizu T., Kohno M., Mori A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 657:1994;207-213.
35. Olanow C.W. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:1993;439-444.
36. Rabey J.M., Passeltine P., Markey K., Asano T., Goldstein M. Stimulation of pre- and post-synaptic dopamine receptors by an ergoline and by a partial ergoline. Brain Res. 225:1981;347-356.
37. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J. Neurochem. 52:1989;515-520.
38. Sawada H., Ibi M., Kihara T., Urushitani M., Akaike A., Kimura J., Shimohama S. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 44:1998;110-119.
39. Scigliano G., Musicco M., Soliveri P., Piccolo I., Girotti F., Giovannini P., Caraceni T. Mortality associated with early and late levodopa therapy initiation in PD. Neurology. 40:1990;265-269.
40. Spencer Smith T., Parker W.D.J., Bennett J.P. Levodopa increases nigral production of hydroxyl radicals in vivo; potential levodopa toxicity? NeuroReport. 5:1994;1009-1011.
41. Spina M.B., Cohen G. Dopamine turnover and glutathione oxidation: implications for PD. Proc. Natl. Acad. Sci. U.S.A. 86:1989;1398-1400.
42. Tanaka M., Sotomatsu A., Yoshida T., Hirai S. Inhibitory effects of bromocriptine on phospholipid peroxidation induced by DOPA and iron. Neurosci. Lett. 183:1995;116-119.
43. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 27:1969;502-522.
44. Yoshikawa T., Minamiyama Y., Naito Y., Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J. Neurochem. 62:1994;1034-1038.
45. Yurek D.M., Steece-Collier K., Collier T.J., Sladek J.R. Jr. Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting. Exp. Brain Res. 86:1991;97-107.